This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Inovio Pharmaceuticals (INO), Elevance Health (ELV)

Tipranks - Tipranks - Fri Apr 10, 6:44AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inovio Pharmaceuticals (INO), Elevance Health (ELV) and Nurix Therapeutics (NRIX) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Inovio Pharmaceuticals (INO)

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $6.00. The company’s shares closed last Wednesday at $1.09.

According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of 4.8% and a 38.6% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Acrivon Therapeutics, Inc., and Arrowhead Pharmaceuticals. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inovio Pharmaceuticals with a $4.50 average price target.

See today’s best-performing stocks on TipRanks >>

Elevance Health (ELV)

In a report released today, Jason Cassorla from Guggenheim reiterated a Buy rating on Elevance Health, with a price target of $396.00. The company’s shares closed last Wednesday at $318.23.

According to TipRanks.com, Cassorla is a 1-star analyst with an average return of -4.2% and a 44.6% success rate. Cassorla covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Molina Healthcare, and Acadia Healthcare. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Elevance Health with a $378.71 average price target, representing a 20.0% upside. In a report issued on March 30, Bernstein also maintained a Buy rating on the stock with a $384.00 price target.

Nurix Therapeutics (NRIX)

Truist Financial analyst Gregory Renza maintained a Buy rating on Nurix Therapeutics today and set a price target of $30.00. The company’s shares closed last Wednesday at $15.60.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 17.8% and a 46.4% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $30.82 average price target, implying an 86.0% upside from current levels. In a report issued on April 2, Wells Fargo also maintained a Buy rating on the stock with a $29.00 price target.

Read More on INO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).